Caredx Stock News

CareDxs Innovative, Non-Invasive Blood Tests Are Being Used as a Critical Tool to Help Assess Organ Health CareDxs Innovative, Non-Invasive Blood Tests Are Being Used as a Critical Tool to Help Assess Organ Health

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front, the Food and Drug A

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically d

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – today announced it will report financial results for the fourth quarter and full year 2021 after market close on Thursday, February 24, 2022. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically dif

More than 100,000 Americans Are on the National Transplant Waiting List and Nearly 20 Die Each Day Waiting for an Organ Transplant They Desperately Need More than 100,000 Americans Are on the National

CareDx Inc (NASDAQ:CDNA)s traded shares stood at 0.39 million during the last session, with the companys beta value hitting 0.67. At the close of trading, the stocks price was $43.20, to imply a decrease of -2.33% or -$1.03 in intraday trading. The CDNA shares 52-week high remains $96.88, putting it -124.26% down since that peak Now Is The Time To Build A Position In CareDx Inc (NASDAQ:CDNA) Read More »

CareDx Supported Education Aims to Reach Underrepresented Minorities with Information on Reducing Cardiovascular Complications Which Can Lead to Kidney Transplant Failure CareDx Supported Education Ai

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically di

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically diff

SOUTH SAN FRANCISCO, Calif., Jan. 20, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically di

CareDx <> said a study showed that AlloSure Kidney is an early and accurate measure of allograft injury in routine organ transplant surveillance and is able to predict

ADMIRAL Study Shows AlloSure Detects Clinical and Subclinical ABMR and TCMR, and Predicts Long-Term Outcomes for Kidney Transplant Patients AlloSure Showed 62% Improvement Over Standard of Care Serum Creatinine SOUTH SAN FRANCISCO, Calif., Jan. 12, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ: CDNA ) The Transplant Company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients today announced the publication 1 of results from a large, multicenter prospective study showing that AlloSure® Kidney is an early and accurate measure of allograft injury in routine organ transplant surveillance, and is able to predict long-term graft survival outcomes. The ADMIRAL study , Assessing AlloSure Dd-cfDNA Monitoring Insights of Renal Allografts With Longitudinal Surveillance (NCT04566055), monitored 1,092 kidney transplant patients, in a real-world setting, from seven transplant centers for up to three years using the AlloSure Kidney donor-derived cell-free DNA (dd-cfDNA) as part of the standard of care.

The stock price of CareDx, Inc. (Nasdaq: CDNA) increased by 18.48% in the most recent trading session. This is why it happened.

CareDx <> expects prelim Q4 revenue to be in the range of $78.6 to $79M, representing Y/Y growth of 34% to 35%.While the company reported record testing volume and revenues